Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Targeting CDK16 Abrogates Growth-Factor Mediated TKI Resistance in AML

Meenu Kesarwani, Zachary Kincaid, Mohammad Azhar, Mohammad Azam

Blood (2024) 144 (Supplement 1): 5786.

https://doi.org/10.1182/blood-2024-211448

Published: 2024

Journal Articles

Enhanced Mitochondrial Priming By Momelotinib Confers Superior In Vivo Efficacy in Combination with Venetoclax Compared to Gilteritinib or Ruxolitinib

Zachary Kincaid, Sekhu Ansari, Mohammad Azhar, Meenu Kesarwani, Mohammad Azam

Blood (2024) 144 (Supplement 1): 5814.

https://doi.org/10.1182/blood-2024-211412

Published: 2024

Journal Articles

DUSP1 Specific Protac Selectively Targets the JAK2 V617F Expressing Cells

Meenu Kesarwani, Mohammad Azhar, Sekhu Ansari, Zachary Kincaid, Mohammad Azam

Blood (2023) 142 (Supplement 1): 3156.

https://doi.org/10.1182/blood-2023-189845

Published: 2023

Journal Articles

Targeting the Negative-Feedback Inhibitor of MAPK Signaling Selectively Eliminates Leukemic Clone in Cnl/Acml

Meenu Kesarwani, Mohammad Azhar, Zachary Kincaid, Mohammad Azam

Blood (2022) 140 (Supplement 1): 9582–9583.

https://doi.org/10.1182/blood-2022-167291

Published: 2022

Journal Articles

Rational Polypharmacological Targeting of FLT3, JAK2, ABL and ERK1 By Pluripotin Suppresses the Adaptive Resistance to FLT3 Inhibitors in AML

Mohammad Azhar, Zachary Kincaid, Meenu Kesarwani, Tahir Latif, Sekhu Ansari, William Seibel, Mohammad Azam

Blood (2022) 140 (Supplement 1): 3101–3102.

https://doi.org/10.1182/blood-2022-167484

Published: 2022

Journal Articles

Momelotinib Is a Highly Potent Inhibitor of FLT3-Mutant AML

Mohammad Azhar, Zachary Kincaid, Meenu Kesarwani, Mark Wunderlich, Tahir Latif, Daniel Starczynowski, Mohammad Azam

Blood (2021) 138 (Supplement 1): 206.

https://doi.org/10.1182/blood-2021-148822

Published: 2021

Journal Articles

Toso regulates the balance between apoptotic and nonapoptotic death receptor signaling by facilitating RIP1 ubiquitination

Xuan-Hung Nguyen, Philipp A. Lang, Karl S. Lang, Dieter Adam, Gulnar Fattakhova, Niko Föger, Mohammad Azhar Kamal, Patricia Prilla, Sabine Mathieu, Christina Wagner, Tak Mak, Andrew C. Chan, Kyeong-Hee Lee

Blood (2011) 118 (3): 598–608.

https://doi.org/10.1182/blood-2010-10-313643

Published: 2011

Includes: Supplemental data

NARROW

Targeting CDK16 Abrogates Growth-Factor Mediated TKI Resistance in AML

Enhanced Mitochondrial Priming By Momelotinib Confers Superior In Vivo Efficacy in Combination with Venetoclax Compared to Gilteritinib or Ruxolitinib

DUSP1 Specific Protac Selectively Targets the JAK2 V617F Expressing Cells

Targeting the Negative-Feedback Inhibitor of MAPK Signaling Selectively Eliminates Leukemic Clone in Cnl/Acml

Rational Polypharmacological Targeting of FLT3, JAK2, ABL and ERK1 By Pluripotin Suppresses the Adaptive Resistance to FLT3 Inhibitors in AML

Momelotinib Is a Highly Potent Inhibitor of FLT3-Mutant AML

Toso regulates the balance between apoptotic and nonapoptotic death receptor signaling by facilitating RIP1 ubiquitination

Email alerts

ASH Publications

American Society of Hematology

Targeting CDK16 Abrogates Growth-Factor Mediated TKI Resistance in AML

Enhanced Mitochondrial Priming By Momelotinib Confers Superior In Vivo Efficacy in Combination with Venetoclax Compared to Gilteritinib or Ruxolitinib

DUSP1 Specific Protac Selectively Targets the JAK2 V617F Expressing Cells

Targeting the Negative-Feedback Inhibitor of MAPK Signaling Selectively Eliminates Leukemic Clone in Cnl/Acml

Rational Polypharmacological Targeting of FLT3, JAK2, ABL and ERK1 By Pluripotin Suppresses the Adaptive Resistance to FLT3 Inhibitors in AML

Momelotinib Is a Highly Potent Inhibitor of FLT3-Mutant AML

Toso regulates the balance between apoptotic and nonapoptotic death receptor signaling by facilitating RIP1 ubiquitination

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only